Barclays Adjusts Elevance Health (ELV) PT to $393 While Maintaining Overweight Rating

Elevance Health Inc. (NYSE:ELV) is one of the most undervalued large cap stocks to invest in now.. On January 30, Barclays lowered the firm’s price target on Elevance Health to $393 from $404 and kept an Overweight rating on the shares.

On January 29, Guggenheim analyst Jason Cassorla also lowered the firm’s price target on Elevance Health to $396 from $414 and maintained a Buy rating on recalibrated 2026 estimates following the company’s Q4 2025 report.

However, on the same day, Deutsche Bank raised the firm’s price target on Elevance Health Inc. (NYSE:ELV) to $332 from $320 while maintaining a Hold rating on the shares. This decision was made as the firm suggested that the company’s 2026 outlook may represent a floor.

Furthermore, UBS also lowered the firm’s price target on Elevance Health to $400 from $425 with a Buy rating.

Elevance Health Inc. (NYSE:ELV), together with its subsidiaries, operates as a health benefits company in the US. It has four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other.

While we acknowledge the potential of ELV as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.